UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 290

Sortiert nach

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Annals of oncology, 2015-12, Vol.26 (12), p.2375-2391

2015

Volltextzugriff (PDF)

Characterization of on-target adverse events caused by TRK inhibitor therapy

Annals of oncology, 2020-09, Vol.31 (9), p.1207-1215

2020

Volltextzugriff (PDF)

Light trapping in ultrathin plasmonic solar cells

Optics express, 2010-06, Vol.18 Suppl 2 (S2), p.A237-A245

2010

Volltextzugriff (PDF)

P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1191-S1192

2019

Volltextzugriff (PDF)

Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”

Annals of oncology, 2016-07, Vol.27 (7), p.1362-1362

2016

Volltextzugriff (PDF)

A dissolution-diffusion sliding model for soft rock grains with hydro-mechanical effect

Journal of Rock Mechanics and Geotechnical Engineering, 2018-06, Vol.10 (3), p.457-467

2018

Volltextzugriff (PDF)

Disparities in Stage at Presentation among Hispanic and Latinx Patients with Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e14-e14

2023

Volltextzugriff (PDF)

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

The New England journal of medicine, 2021-06, Vol.384 (25), p.2371-2381

2021

Volltextzugriff (PDF)

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Annals of oncology, 2018-10, Vol.29 (10), p.2085-2091

2018

Volltextzugriff (PDF)

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Annals of oncology, 2015-07, Vol.26 (7), p.1421-1427

2015

Volltextzugriff (PDF)

Expanding the nanotherapeutic toolbox for non-small-cell lung cancer

Annals of oncology, 2021-01, Vol.32 (1), p.9-11

2021

Volltextzugriff (PDF)

MA06.08 Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S120-S121

2023

Volltextzugriff (PDF)

Chemotherapy remains an essential element of personalized care for persons with lung cancers

Annals of oncology, 2016-10, Vol.27 (10), p.1829-1835

2016

Volltextzugriff (PDF)

P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S354

2023

Volltextzugriff (PDF)

NURBS-based IGA of viscous fluid movement with special-shaped small gaps in hybrid bearing

Applied mathematical modelling, 2022-09, Vol.109, p.401-425

2022

Volltextzugriff (PDF)

Prospective, Cell-Free Circulating Tumor DNA (ctDNA) Profiling in Locally Advanced Lung Cancer Treated with Chemoradiation

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e31-e31

2023

Volltextzugriff (PDF)

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

Annals of oncology, 2019-04, Vol.30 (4), p.597-603

2019

Volltextzugriff (PDF)

The Impact of Co-Alterations on Outcomes after Local Therapy for Patients with KRAS-Mutant Lung Adenocarcinoma Brain Metastases

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e101-e102

2023

Volltextzugriff (PDF)

151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

Annals of oncology, 2023-10, Vol.34, p.S241-S242

2023

Volltextzugriff (PDF)

1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

Annals of oncology, 2023-10, Vol.34, p.S762-S763

2023

Volltextzugriff (PDF)

657MO Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors

Annals of oncology, 2023-10, Vol.34, p.S462-S463

2023

Volltextzugriff (PDF)

Multidisciplinary optimization of liquid cooled heat sinks with compound jet/channel structures arranged in a multipass configuration

Applied thermal engineering, 2021-08, Vol.195, p.117159, Article 117159

2021

Volltextzugriff (PDF)

OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S8

2022

Volltextzugriff (PDF)

EP05.01-014 Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S272-S273

2022

Volltextzugriff (PDF)

MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S118-S119

2023

Volltextzugriff (PDF)

1 – 25 von 290

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(257)
Mit Volltextzugriff
(279)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(173)
Life Sciences & Biomedicine
(86)
Technology
(63)
Physical Sciences
(58)
Physics
(53)
Humans
(50)
Engineering
(30)
Materials Science
(29)
Female
(27)
Male
(24)
Adult
(22)
Biological And Medical Sciences
(22)
Physics, Applied
(21)
Middle Aged
(20)
Oncology
(20)
Exact Sciences And Technology
(19)
Materials Science, Multidisciplinary
(19)
Aged
(17)
Animals
(16)
Engineering, Electrical & Electronic
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Characterization of on-target adverse events caused by TRK inhibitor therapy

Light trapping in ultrathin plasmonic solar cells

P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer

Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”

A dissolution-diffusion sliding model for soft rock grains with hydro-mechanical effect

Disparities in Stage at Presentation among Hispanic and Latinx Patients with Non-Small Cell Lung Cancer

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Expanding the nanotherapeutic toolbox for non-small-cell lung cancer

MA06.08 Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC

Chemotherapy remains an essential element of personalized care for persons with lung cancers

P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers

NURBS-based IGA of viscous fluid movement with special-shaped small gaps in hybrid bearing

Prospective, Cell-Free Circulating Tumor DNA (ctDNA) Profiling in Locally Advanced Lung Cancer Treated with Chemoradiation

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

The Impact of Co-Alterations on Outcomes after Local Therapy for Patients with KRAS-Mutant Lung Adenocarcinoma Brain Metastases

151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

657MO Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors

Multidisciplinary optimization of liquid cooled heat sinks with compound jet/channel structures arranged in a multipass configuration

OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

EP05.01-014 Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer

MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC

Suchergebnisse filtern